Danielle Brill
Stock Analyst at Raymond James
(2.07)
# 3,019
Out of 4,984 analysts
83
Total ratings
40.28%
Success rate
-4.4%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $391.36 | - | 3 | Sep 3, 2025 | |
| IRON Disc Medicine | Initiates: Buy | $86 | $60.34 | +42.53% | 6 | Jul 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Buy | $385 | $461.24 | -16.53% | 1 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $32.29 | +48.65% | 8 | Jul 21, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $56 | $54.51 | +2.73% | 1 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $16.01 | +299.75% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $140.90 | +15.68% | 6 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $66 | $51.49 | +28.18% | 1 | Jul 21, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $30 | $21.33 | +40.65% | 1 | Jul 21, 2025 | |
| JCAP Jefferson Capital | Initiates: Buy | $24 | $18.16 | +32.16% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $14.47 | +259.36% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $13.26 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $53.94 | +46.46% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $9.26 | +94.38% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $36 | $15.29 | +135.45% | 4 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $18.10 | +728.73% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $143.68 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $752.32 | -19.58% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $23.96 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $35.69 | +40.10% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $36.72 | +38.89% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.27 | +1,275.52% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $59.69 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.51 | - | 5 | Jun 27, 2023 |
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $391.36
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $60.34
Upside: +42.53%
Alnylam Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $385
Current: $461.24
Upside: -16.53%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $32.29
Upside: +48.65%
Palvella Therapeutics
Jul 21, 2025
Initiates: Buy
Price Target: $56
Current: $54.51
Upside: +2.73%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $16.01
Upside: +299.75%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $140.90
Upside: +15.68%
BridgeBio Pharma
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $51.49
Upside: +28.18%
Centessa Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $21.33
Upside: +40.65%
Jefferson Capital
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.16
Upside: +32.16%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.47
Upside: +259.36%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $13.26
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $53.94
Upside: +46.46%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $9.26
Upside: +94.38%
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $15.29
Upside: +135.45%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $18.10
Upside: +728.73%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $143.68
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $752.32
Upside: -19.58%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $23.96
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $35.69
Upside: +40.10%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $36.72
Upside: +38.89%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.27
Upside: +1,275.52%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $59.69
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.51
Upside: -